priors.science/reviews/acute-coronary-syndrome-management

Acute Coronary Syndrome Management

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

20claims tracked

136primary papers reviewed

2 Jun 2026latest evidence review

Weeklyre-scored against new papers

2 Established · 10 Likely · 8 Uncertain · 0 Doubtful | four-reviewer panel · PICO Framework

SignalClaimStandingEvidence certaintyCorpus

StableFondaparinux reduces major bleeding versus enoxaparin in NSTE-ACSAnticoagulationEstablished88%—

StableHigh-intensity statins reduce MACE in acute coronary syndrome patientsLipid LoweringEstablished88%—

StablePCSK9 inhibitors added to statins reduce MACE post-ACSPcsk9 InhibitionLikely81%—

StableACE inhibitors reduce mortality in ACS with reduced ejection fractionRaas BlockadeLikely80%—

StableMajor bleeding post-ACS independently predicts 30-day mortalityAnticoagulationLikely79%—

StableEzetimibe added to statins reduces cardiovascular events post-ACSLipid LoweringLikely78%—

StableBeta-blockers reduce mortality in ACS with reduced ejection fractionBeta Blocker TherapyLikely77%—

StableExercise-based cardiac rehabilitation reduces cardiovascular mortality post-MICardiac RehabilitationLikely77%—

StablePotent P2Y12 inhibitors reduce MACE versus clopidogrel post-ACSAntiplatelet TherapyLikely74%—

StableComplete revascularization reduces MACE versus incomplete in multivessel ACSRevascularizationLikely72%—

StableExercise-based cardiac rehabilitation reduces reinfarction risk post-MICardiac RehabilitationLikely70%—

StableDAPT de-escalation to clopidogrel is non-inferior for MACE post-ACSAntiplatelet TherapyLikely69%—

StableCABG reduces long-term mortality versus PCI in multivessel ACSRevascularizationUncertain60%—

StableColchicine reduces MACE after myocardial infarctionAnti InflammatoryUncertain57%—

StableP2Y12 monotherapy after short DAPT reduces bleeding without increasing MACEAntiplatelet TherapyUncertain56%—

StableSGLT2 inhibitors reduce heart failure hospitalization post-ACSSglt2 InhibitionUncertain53%—

StableBeta-blockers lack mortality benefit in ACS with preserved ejection fractionBeta Blocker TherapyUncertain52%—

StableRAAS blockade provides no clear mortality benefit in ACS with preserved ejection fractionRaas BlockadeUncertain51%—

StableFFR-guided PCI and CABG have similar outcomes in multivessel NSTE-ACSRevascularizationUncertain51%—

StableSGLT2 inhibitors benefit post-ACS patients without diabetesSglt2 InhibitionUncertain46%—

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely65–84%Well supported, with some gaps or indirect evidence.

Uncertain40–64%Mixed or limited evidence. Genuinely open.

Doubtful15–39%Little support; the weight of evidence leans against it.

Refuted< 15%The evidence contradicts it — confidently false as stated.

Recent signal

strengthenedNew evidence raised the certainty since the last review.

weakenedNew evidence lowered the certainty since the last review.

newA claim added to the review recently.

StableNo recent change to the standing.

Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.

Update your priors.Track this topic